| Theme | Autoimmune Pancreatitis -- Present Status & Future Perspectives | |
|---|---|---|
| Title | Extrapancreatic Lesions of Autoimmune Pancreatitis | |
| Publish Date | 2018/02 | |
| Author | Nao Fujimori | Hepatology and Pancreatology, Kyushu University Hospital |
| Author | Tetsuhide Ito | Neuroendocrine Tumor Centre, Fukuoka Sanno Hospital, International University of Health and Welfare |
| Author | Masami Miki | Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University |
| Author | Yuichi Tachibana | Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University |
| Author | Ken Kawabe | Hepatology and Pancreatology, Kyushu University Hospital |
| Author | Yoshihiro Ogawa | Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University |
| [ Summary ] | Recently, the concept of IgG4‒related disease (IgG4‒RD) was established from clinical experience and research on autoimmune pancreatitis (AIP) in Japan. AIP is now regarded as a pancreatic lesion of IgG4‒RD, and frequently accompanied by extrapancreatic lesions including sclerosing cholangitis, sclerosing sialadenitis, retroperitoneal fibrosis, pulmonary disease, and kidney disease. The diagnostic criteria for each lesion have been proposed, and it is important to recognize AIP as a systemic disease. Extrapancreatic lesions, as well as AIP, respond to steroid therapy in most cases. However, the relapse rate of extrapancreatic lesions is relatively high and the predictive factors for relapse remain unclear. It is well known that the onset of extrapancreatic lesion is heterochronic or synchronized to the onset of AIP. Therefore, gastroenterologists should pay attention to general symptoms during the treatment and follow‒up of AIP. | |